Mitochondriotropic cationic vesicles: a strategy towards mitochondrial gene therapy.

Area of Science:

• Mitochondrial biology
• Gene therapy
• Nanomedicine

Background:

• Mitochondrial DNA (mtDNA) defects are linked to numerous diseases, with limited treatment options due to the central role of oxidative metabolism.
• Conventional therapies are ineffective for mtDNA defects because the metabolic pathway cannot be bypassed.
• Existing gene therapy approaches for mitochondria are theoretical, requiring specific delivery vectors.

Purpose of the Study:

• To develop a novel, mitochondria-specific vector for DNA delivery.
• To overcome the limitations of current treatments for mitochondrial DNA defects.
• To explore gene therapeutic strategies for mitochondrial diseases.

Main Methods:

• Analysis of dequalinium's self-assembly properties for DNA delivery.
• Development and preparation of dequalinium-based vesicles, termed DQAsomes.
• Testing DQAsome-DNA complex binding, protection, and selective release using cardiolipin-rich liposomes.

Main Results:

• DQAsomes were successfully prepared from dequalinium, a mitochondria-accumulating compound.
• DQAsomes demonstrated efficient DNA binding and protection.
• Selective DNA release was observed at liposomes mimicking mitochondrial membranes, indicating targeted delivery potential.

Conclusions:

• DQAsomes represent a novel strategy for mitochondria-specific DNA delivery.
• These DQAsomes show promise as the first vector capable of delivering DNA to mitochondria in living cells.
• This breakthrough could pave the way for effective gene therapies for mitochondrial diseases.